• Product Name: Poliovirus Vaccine Inactivated (Monkey Kidney Cell)
• Tradename: IPOL
• Manufacturer: Sanofi Pasteur, SA
• Vaccine Ontology ID: VO_0000054
• CDC CVX code: 10
• Type: Inactivated or "killed" vaccine
• Status: Licensed
• Location Licensed: USA (License #1724)
• Host Species for Licensed Use: Human
• Antigen: Three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett).
• Preparation: IPOL is a sterile inactivated vaccine suspension of three types of poliovirus: Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett). Each of the three strains of poliovirus is individually grown in vero cells, a continuous line of monkey kidney cells cultivated on microcarriers. After clarification and filtration, viral suspensions are concentrated by ultrafiltration, and purified by liquid chromatography. After re-equilibration of the purified viral suspension, the monovalent viral suspensions are inactivated at +37°C for at least 12 days with 1:4000 formalin. Each dose (0.5 mL) of trivalent vaccine is formulated to contain 40 D antigen units of Type 1, 8 D antigen units.
• Immunization Route: Intramuscular injection (i.m.)
• Storage: 2°C to 8°C (35°F to 46°F). The vaccine must not be frozen (FDA: IPOL).
• Contraindication: The vaccine should not be administered to persons with a history of hypersensitivity to any component of the vaccine (FDA: IPOL).
• Description: All children should receive four doses of inactivated poliovirus vaccine (IPV) at ages 2, 4, 6 to 18 months and 4 to 6 years (FDA: IPOL).

Human Response

• Immune Response: In most clinical studies performed with this vaccine, the seroconversion rates have always been between 80% and 100% (FDA: IPOL).
• Side Effects: The most common side effects reported include injection site reactions, fever, irritability and fatigue (FDA: IPOL).